Structural & Congenital Heart Disease

The considerable survival advantage observed in female patients undergoing transcatheter aortic valve implantation (TAVI) during the procedure’s earlier years has diminished in the contemporary TAVI era, according to research out of Petah Tikva, Israel, meaning men and women are seeing similar outcomes post-procedure.

With CMS set to release a new National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR) next June, researchers at TCT 2018 weighed in on what the new procedural volume thresholds should look like.

Transcatheter aortic valve replacement (TAVR) was easily the treatment of choice in German patients with severe stenosis at intermediate surgical risk from 2012 to 2014, according to a registry study, with both TAVR and surgical AVR (SAVR) carrying a 3.6 percent risk of in-hospital mortality.

Emergency department visits for children with congenital heart disease (CHD) are getting more expensive over time but mortality rates are improving, according to an analysis of more than 420,000 CHD-related trips to the ED over a nine-year period.

Heart failure (HF) patients who experience moderate functional mitral regurgitation (FMR) for at least six months after cardiac resynchronization therapy (CRT) are at an increased risk for death, researchers suggest in a study published this week.

Mitral valve prolapse (MVP)—a common condition that’s rarely serious—might boost heart patients’ risk for sudden cardiac death (SCD), researchers reported in the BMJ journal Heart this week.

OAC-ALONE, the first randomized trial to test the efficacy of oral anticoagulation (OAC) alone against combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation and stable coronary artery disease, was unable to establish noninferiority of OACs to dual therapy, according to data presented at the 30th annual TCT conference in San Diego.

SAN DIEGO — General and local anesthesia are comparably safe and effective during transcatheter aortic valve replacement (TAVR) procedures, according to the first randomized trial to compare the two approaches.

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

Sustained elevated blood pressure can increase a patient’s risk for both aortic valve stenosis and aortic regurgitation, according to an analysis of 5.4 million non-CVD patients in the U.K.

Gregg W. Stone, MD, had the unenviable task of condensing the 255-page agenda for next weekend’s Transcatheter Cardiovascular Therapeutics (TCT) meeting into a handful of highlights during a 12-minute media briefing on Thursday, Sept. 13.

Three decades after the first Transcatheter Cardiovascular Therapeutics conference, TCT.18’s organizers are moving “toward a more practical approach,” says Cardiovascular Research Foundation CEO Juan Granada, MD.